Maguire Niall, Moloney Andrea, Fic Krzysztof
Bedford Medical Centre, Navan, Ireland.
University College Dublin, School of Medicine, Dublin, Ireland.
Ir J Med Sci. 2025 Feb;194(1):1-3. doi: 10.1007/s11845-024-03804-4. Epub 2024 Oct 23.
Prostate-specific antigen (PSA) testing is not recommended as a population screening measure for prostate cancer. PSA testing is nevertheless widespread and is associated with harm due to false-positive test results, overdiagnosis and economic costs.
This study sought to document the exposure of patients to PSA testing over a decade in a general medical practice setting.
Laboratory results for each year were extracted from the clinical record. A chart review was undertaken for cases of prostate cancer.
We report 13,743 PSA results in 3313 men. In any year, 18% of all men and 33% of men aged over 50 years had at least one PSA test. Between 4.8 and 21% of first tests exceeded age normal values depending on age. There were 113 incident cancers in the study interval of which 84 (74%) were screen detected. Mortality was lower in screen-detected than symptomatic cancers.
Men at our practice are significantly exposed to PSA testing. We found evidence of possible overdiagnosis.
不建议将前列腺特异性抗原(PSA)检测作为前列腺癌的人群筛查手段。然而,PSA检测仍广泛应用,且因假阳性检测结果、过度诊断和经济成本而带来危害。
本研究旨在记录在普通医疗环境中患者在十年间接受PSA检测的情况。
从临床记录中提取每年的实验室检查结果。对前列腺癌病例进行病历审查。
我们报告了3313名男性的13743份PSA检测结果。在任何一年,所有男性中有18%以及50岁以上男性中有33%至少接受过一次PSA检测。根据年龄不同,首次检测结果中有4.8%至21%超过年龄正常值。在研究期间有113例新发癌症,其中84例(74%)是筛查发现的。筛查发现的癌症患者死亡率低于有症状的癌症患者。
在我们诊所,男性大量接受PSA检测。我们发现了可能存在过度诊断的证据。